跳转至内容
Merck
CN
  • Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases.

Cytotoxic Synergy Between Cytokines and NSAIDs Associated With Idiosyncratic Hepatotoxicity Is Driven by Mitogen-Activated Protein Kinases.

Toxicological sciences : an official journal of the Society of Toxicology (2015-05-09)
Ashley R Maiuri, Anna B Breier, Lukas F J Gora, Robert V Parkins, Patricia E Ganey, Robert A Roth
摘要

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequent causes of idiosyncratic, drug-induced liver injury (IDILI). Mechanisms of IDILI are unknown, but immune responses are suspected to underlie them. In animal models of IDILI, the cytokines tumor necrosis factor-alpha (TNFα) and interferon-gamma (IFNγ) are essential to the pathogenesis. Some drugs associated with IDILI interact with cytokines to kill hepatocytes in vitro, and mitogen-activated protein kinases (MAPKs) might play a role. We tested the hypothesis that caspases and MAPKs are involved in NSAID/cytokine-induced cytotoxicity. NSAIDs that are acetic acid (AA) derivatives and associated with IDILI synergized with TNFα in causing cytotoxicity in HepG2 cells, and IFNγ enhanced this interaction. NSAIDs that are propionic acid (PA) derivatives and cause IDILI that is of less clinical concern also synergized with TNFα, but IFNγ was without effect. Caspase inhibition prevented cytotoxicity from AA and PA derivative/cytokine treatment. Treatment with a representative AA or PA derivative induced activation of the MAPKs c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38. Inhibition of either JNK or ERK reduced cytotoxicity from cytokine interactions with AA derivatives. In contrast, an ERK inhibitor potentiated cytotoxicity from cytokine interactions with PA derivatives. An AA derivative but not a PA derivative enhanced IFNγ-mediated activation of STAT-1, and this enhancement was ERK-dependent. These findings raise the possibility that some IDILI reactions result from drug/cytokine synergy involving caspases and MAPKs and suggest that, even for drugs within the same pharmacologic class, synergy with cytokines occurs by different kinase signaling mechanisms.

材料
Product Number
品牌
产品描述

Sigma-Aldrich
L-谷氨酰胺, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, ≥98.0% (titration)
Sigma-Aldrich
L-谷氨酰胺, ReagentPlus®, ≥99% (HPLC)
SAFC
L-谷氨酰胺
Sigma-Aldrich
肿瘤坏死因子-α 人, Xeno-free, recombinant, expressed in HEK 293 cells, suitable for cell culture
SAFC
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇
Sigma-Aldrich
TNF-α 人, Animal-component free, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
L-谷氨酰胺, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
肿瘤坏死因子-α 人, TNF-α, recombinant, expressed in E. coli, powder, suitable for cell culture
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
L-谷氨酰胺, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-谷氨酰胺
Sigma-Aldrich
三(叔丁氧基)硅烷醇, 99.999%
SAFC
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇
Sigma-Aldrich
L-谷氨酰胺, Vetec, reagent grade, ≥99%
Sigma-Aldrich
2-二(2-羟乙基)氨基-2-羟甲基-1,3-丙二醇, Vetec, reagent grade, ≥98%, RNase and DNase free